Biotech Values

[oc631]

They can use data from this ph3b trial along with data they have now including sofobusvir/IFNR currently pending at EMA/FDA to submit full package in Russian if they want to.

Using interferon-based results to make a case for a weak oral combo is non-sense. The data from the 3B study, if released, will confirm this.

If Sofo/Riba is approved for GT1 patients in Russia it will be due to ignorance and/or corruption and it will bring the moral hazard, re-treatment issue front and center.